Thalidomide and thrombosis;Thalidomide et thromboses

Annales de Dermatologie et de Venereologie

Volumn 127, Issue 2, 2000, Pages 171-174

  Flageul, B ^a   Wallach, D ^b   Cavelier Balloy, B ^a   Bachelez, H ^a   Carsuzaa, F ^c   Dubertret, L ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b Paris Descartes University   (France)

^c Service de Dermatologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DAPSONE; HYDROXYCHLOROQUINE; PREDNISONE; THALIDOMIDE;

ADULT; ARTERY THROMBOSIS; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISCOID LUPUS ERYTHEMATOSUS; DRUG SAFETY; FEMALE; HUMAN; MALE; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOGENESIS; VEIN THROMBOSIS;

ADULT; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK FACTORS; THALIDOMIDE; THROMBOSIS;

EID: 0034105132     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ochonisky S, Revuz J. Thalidomide use in dermatology. Eur J Dermatol 1994;4:9-15.
2. Chalderon P, Anzilotti M, Phelps R. Thalidomide in dermatology. New indications for an old drug. Int J Dermatol 1997;36:881-7.
3. Ishii Y, Nagasawa K, Mayumi T, Niho Y. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 1990;49:387-90.
4. Petri M, Hochhberg M, Hellmann D, Bell W, Goldman D. Incidence of and predictors of thrombotic events in SLE : Protective role of hydroxychloroquine. Arthritis Rheum 1992;35 (suppl 9) : S54.
5. Gulko PS, Reveille JD, Koopman WJ, Burgard SL, Bartolucci AA, Alarcon GS. Anticardiolipin antibodies in systemic lupus erythematosus : clinical correlates, HLA associations and impact on survival. J Rheum 1993;49: 1684-93.
6. Bertrand E, Cloitre B, Ticolat R, Bile RK, Gautier C, Abiyou GO, et al. Antiaggregation action of chloroquine. Med Trop 1990;50:143-6.
7. Carter A, Eban R. Prevention of post operative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J 1974;3:94-5.
8. Wallace DJ, Linker-Israeli M, Metzger AL, Stechner VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993;2 : S13-S15.
9. Edwards MH, Pierrangeli S, Liu XW, Barker JH, Anderson G, Harris N. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997;96:4384.
10. Bessis D, Guillot B, Monpoint S, Dandurand M, Guilhou JJ. Thalidomide for systemic lupus erythematosus. Lancet 1992;339:549-50.
11. Atra E, Sato El. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheum 1993;11:487-93.
12. Samsoen M, Grosshans E, Basset A. La thalidomide dans le traitement du lupus érythémateux chronique. Ann Dermatol Venereol 1980;107:515-23.
13. Knop J, Bnosmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of chronic discoid lupus erythematosus. Br J Dermatol 1983;108:461-6.
14. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakyl S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. Ann Intern Med 1998;128:443-50.
15. Petter C. Early foetal thrombosis induced by thalidomide in mouse : a possible explanation for teratogenicity. Experentia 1977;33:1384-6.
16. Bucckle RM. Blood pyruvic acid in thalidomid neuropathy. Br Med J 1963;2:973-5.
17. Nogueira AC, Neubert R, Helge H, Neubert D. Thalidomide and the immune system. Part 3 - Simultaneous up and down regulation of different integrin receptors on human white blood cells. Life Sci 1994;55: 77-92.
18. Neubert R, Hinz N, Thiel R, Neubert D. Down regulation of adhesion receptors on cells of primate embryos as a probable mechanim of teratogenic action of thalidomide. Life Sci 1996;58:295-316.
19. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
20. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Vôlcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Arch Clin Exp Ophtalmol 1998;236:461-6.